Various aspects and embodiments herein relate to recombinant proteins with at least one protease recognition sequence, wherein the recombinant proteins can be inactivated by a cognate protease and methods of preparing such proteins. In some embodiments, recombinant phosphoglucose isomerase (Pgi) proteins are provided. In other embodiments, recombinant phosphotransacetylase (Pta) proteins are provided. In yet other embodiments, recombinant transketolase A (TktA) proteins are provided.

Described is a method for the production of D-erythrose and acetyl phosphate comprising the enzymatic conversion of D-fructose into D-erythrose and acetyl phosphate by making use of a phosphoketolase. The produced D-erythrose can further be converted into glycolaldehyde by a method for the production of glycolaldehyde comprising the enzymatic conversion of D-erythrose into glycolaldehyde by making use of an aldolase, wherein aldolase is a 2-deoxyribose-5-phosphate aldolase (EC 4.1.2.4) or a fructose-bisphosphate aldolase (EC 4.1.2.13). The produced glycolaldehyde can finally be converted into acetyl phosphate by the enzymatic conversion of the thus produced glycolaldehyde into acetyl phosphate by making use of a phosphoketolase or a sulfoacetaldehyde acetyltransferase.

The present invention relates to a Corynebacterium glutamicum mutant strain having increased L-citrulline productivity, and a method of producing L-citrulline using the same. The Corynebacterium glutamicum mutant strain is capable of producing L-citrulline in high yield and high concentration while inhibiting the production of by-products, because the activity of the protein that is expressed by the NCgl2657 gene therein has been weakened or inactivated.

The invention relates to a genetically engineered bacterium having an enzyme that converts 3-hydroxyisovaleryl-CoA to 3-hydroxyisovalerate and an enzyme that converts 3-hydroxyisovalerate to isobutylene. Typically, the bacterium is capable of producing isobutylene from a gaseous substrate containing CO, CO.sub.2, and/or H.sub.2, such as syngas or an industrial waste gas.

Aspects of the disclosure are directed to genetically modified yeast cells and methods for use. Certain aspects are directed to recombinant yeast cells comprising exogenous nucleic acid sequences encoding phosphotransacetylase and/or phosphoketolase proteins, including a phosphoketolase protein from Clostridium acetobutylicum. Also disclosed are methods for generating recombinant yeast cells and methods of use of such cells for production of one or more products, including lipids, oils, fatty acids, and triacylglycerides.

The present application relates to recombinant microorganisms useful in the biosynthesis of monoethylene glycol (MEG), or optionally MEG and one or more co-product, from one or more hexose feedstock. The present application also relates to recombinant microorganisms useful in the biosynthesis of glycolic acid (GA), or optionally GA and one or more co-product, from one or more hexose feedstock. The present application relates to recombinant microorganisms useful in the biosynthesis of xylitol, or optionally xylitol and one or more co-product, from one or more hexose feedstock. Also provided are methods of producing MEG (or GA or xylitol), or optionally MEG (or GA or xylitol) and one or more co-product, from one or more hexose feedstock using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or the products MEG (or GA or xylitol), or optionally MEG (or GA or xylitol) and one or more co-product.

Geranyl pyrophosphate (GPP) is a key intermediate molecule in the bioproduction of thousands of natural products. Currently, natural products are either cultivated from plants, synthesized via complex chemical synthesis strategies, or through cell-based factories also known as biofoundries. However, in order to replicate the process in a cell free environment, numerous enzymes and cofactors must be utilized making this approach costly and unviable. In order to make this process viable, a new approach was needed that uses fewer enzymes and co-factors. As described herein, the present invention demonstrates that it is possible to create GPP from glycerol through a short and concise biosynthetic pathway outside of the cell.

Modified or recombinant microorganisms are provided herein that can be used to produce one or more amino acids, including, for example, methionine or one or more methionine biosynthetic pathway-derived intermediates or one or more methionine-based products.

The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms by engineering a microorganism for increased carbon flux towards mevalonate production in the following enzymatic pathways: (a) citrate synthase, (b) phosphotransacetylase, (c) acetate kinase, (d) lactate dehydrogenase, (e) malic enzyme, and (f) pyruvate dehydrogenase such that one of more of the enzyme activity is modulated. In addition, production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids can be further enhanced by the heterologous expression of the mvaE and mvaS genes (such as, but not limited to, mvaE and mvaS genes from the organisms Listeria grayi DSM 20601, Enterococcus faecium, Enterococcus gallinarum EG2, and Enterococcus casseliflavus).

A recombinant yeast cell, fermentation compositions, and methods of use thereof are provided. The recombinant yeast cell includes at least one heterologous nucleic acid encoding one or more polypeptide having phosphoketolase activity; phosphotransacetylase activity; and/or acetylating acetaldehyde dehydrogenase activity, wherein the cell does not include a heterologous modified xylose reductase gene, and wherein the cell is capable of increased biochemical end product production in a fermentation process when compared to a parent yeast cell.